{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:12:06Z","timestamp":1780909926805,"version":"3.54.1"},"reference-count":37,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Avon Mesothelioma Foundation"},{"DOI":"10.13039\/100015250","name":"NIHR Bristol Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pleural mesothelioma (PM) is a fatal asbestos-related cancer with a poor and often uncertain prognosis. This study validates the histological proliferation marker Ki67 and evaluates whether its integration into the two-tier tumour grading system can improve prognostication in epithelioid PM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with epithelioid PM were recruited from two longitudinal cohort studies from 2010\u20132023. Diagnostic biopsies were analysed by three pulmonary pathologists. Cox regression determined the relationship between covariables and outcomes. Pearson correlation assessed the association between Ki67 and two-tier grade. A prognostic model combining Ki67 and tumour grade was internally validated using bootstrapping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>98 patients were recruited. Ki67 was strongly predictive of overall survival (OS) and progression-free survival (PFS) and correlated with two-tier tumour grade. 30% was the optimal cut-off, with Ki67 more strongly predictive of OS (hazard ratio (HR) 2.37, 95% CI 1.51\u20133.71) and PFS (HR 2.09, 1.35\u20133.23) than two-tier grade (HR 1.83, 1.13\u20132.97 and HR 1.70, 1.08\u20132.66, respectively). Combining Ki67 and two-tier grade improved prediction of OS and PFS compared with two-tier grade alone. Ki67 stratified patients within each tumour grade, with median survival in the lowest risk group (low Ki67, low grade) of 660.5\u2005days (IQR 329\u20131297) and 300\u2005days (IQR 124\u2013366) in the highest risk group (high Ki67, high grade).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ki67 is a valid surrogate for tumour grade with an optimal cut-off at 30%. Integrating Ki67 into the two-tier grading system enhances prognostic accuracy, improves outcome prediction and would reduce uncertainty for patients and clinicians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01300-2025","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:35:17Z","timestamp":1769776517000},"page":"01300-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ki67 proliferation index augments two-tier tumour grade in prediction of survival and progression-free survival in epithelioid pleural mesothelioma"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6591-2720","authenticated-orcid":false,"given":"Geraldine A.","family":"Lynch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-980X","authenticated-orcid":false,"given":"Yu Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-8979","authenticated-orcid":false,"given":"Pia","family":"Charters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-5550","authenticated-orcid":false,"given":"Avinash","family":"Aujayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saru","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Symonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia O.","family":"Clive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-1997","authenticated-orcid":false,"given":"Rahul","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick A.","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bibby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026060801451070000_12.3.01300-2025.1","unstructured":"Royal College of Physicians National Mesothelioma Audit Report 2020 (for the audit period 2016\u201318). London, RCP, 2020."},{"key":"2026060801451070000_12.3.01300-2025.2","doi-asserted-by":"crossref","first-page":"102111","DOI":"10.1016\/j.ejon.2022.102111","article-title":"The priorities of people with mesothelioma and their carers: a qualitative interview study of trial participation and treatment decisions","volume":"57","author":"Bibby","year":"2022","journal-title":"Eur J Oncol Nurs"},{"key":"2026060801451070000_12.3.01300-2025.3","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2021.08.2146","article-title":"LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743","volume":"32","author":"Peters","year":"2021","journal-title":"Ann Oncol"},{"key":"2026060801451070000_12.3.01300-2025.4","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.cllc.2024.04.011","article-title":"Immediate versus deferred systemic therapy in patients with mesothelioma","volume":"25","author":"Schmid","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2026060801451070000_12.3.01300-2025.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.6.507"},{"key":"2026060801451070000_12.3.01300-2025.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2144"},{"key":"2026060801451070000_12.3.01300-2025.7","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.3390\/jcm12227006","article-title":"Pleural mesothelioma: advances in blood and pleural biomarkers","volume":"12","author":"Sorino","year":"2023","journal-title":"J Clin Med"},{"key":"2026060801451070000_12.3.01300-2025.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"2026060801451070000_12.3.01300-2025.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00953-2019"},{"key":"2026060801451070000_12.3.01300-2025.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000266"},{"key":"2026060801451070000_12.3.01300-2025.11","unstructured":"World Health Organization . Thoracic Tumours: WHO Classification of Tumours. 5th edn. Lyon France: International Agency for Research on Cancer, 2021."},{"key":"2026060801451070000_12.3.01300-2025.12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/his.15106","article-title":"Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"84","author":"Klebe","year":"2024","journal-title":"Histopathology"},{"key":"2026060801451070000_12.3.01300-2025.13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases","volume":"44","author":"Zhang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2026060801451070000_12.3.01300-2025.14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/PAS.0000000000002196","article-title":"Ki-67 proliferation index is associated with tumor grade and survival in pleural epithelioid mesotheliomas","volume":"48","author":"Galeano","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"2026060801451070000_12.3.01300-2025.15","first-page":"659","article-title":"Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2026060801451070000_12.3.01300-2025.16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bjc.2015.9","article-title":"Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study","volume":"112","author":"Ghanim","year":"2015","journal-title":"Br J Cancer"},{"key":"2026060801451070000_12.3.01300-2025.17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G"},{"key":"2026060801451070000_12.3.01300-2025.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378"},{"key":"2026060801451070000_12.3.01300-2025.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2026060801451070000_12.3.01300-2025.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-060850"},{"key":"2026060801451070000_12.3.01300-2025.21","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"2026060801451070000_12.3.01300-2025.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90043-0"},{"key":"2026060801451070000_12.3.01300-2025.23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026060801451070000_12.3.01300-2025.24","doi-asserted-by":"crossref","first-page":"00467\u20132023","DOI":"10.1183\/23120541.00467-2023","article-title":"Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-Meso cohort","volume":"9","author":"Conway","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026060801451070000_12.3.01300-2025.25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"2026060801451070000_12.3.01300-2025.26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"2026060801451070000_12.3.01300-2025.27","first-page":"56","article-title":"Interobserver agreement in histopathological subtyping of malignant pleural mesotheliomas","volume":"37","author":"Mlika","year":"2021","journal-title":"Turk Patoloji Derg"},{"key":"2026060801451070000_12.3.01300-2025.28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.00793.x"},{"key":"2026060801451070000_12.3.01300-2025.29","doi-asserted-by":"publisher","DOI":"10.1078\/0344-0338-00043"},{"key":"2026060801451070000_12.3.01300-2025.30","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000055"},{"key":"2026060801451070000_12.3.01300-2025.31","first-page":"100155","article-title":"Ki67 (MIB-1) as a prognostic marker for clinical decision making before extended pleurectomy decortication in malignant pleural mesothelioma","volume":"2","author":"Belderbos","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2026060801451070000_12.3.01300-2025.32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026060801451070000_12.3.01300-2025.33","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jtho.2018.07.002","article-title":"Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal","volume":"13","author":"Pelosi","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026060801451070000_12.3.01300-2025.34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-13-0246","article-title":"Grading the neuroendocrine tumors of the lung: an evidence-based proposal","volume":"21","author":"Rindi","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2026060801451070000_12.3.01300-2025.35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026060801451070000_12.3.01300-2025.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.007"},{"key":"2026060801451070000_12.3.01300-2025.37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jtho.2024.05.002","article-title":"The international association for the study of lung cancer pleural mesothelioma staging project: proposal for revision of the TNM stage groupings in the forthcoming (ninth) edition of the TNM classification for pleural mesothelioma","volume":"19","author":"Nowak","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01300-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:45:30Z","timestamp":1780908330000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01300-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/23120541.01300-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01300-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}